Advertisement

Journal of Clinical Immunology

, Volume 36, Issue 8, pp 810–817 | Cite as

Asthma and Hypogammaglobulinemia: an Asthma Phenotype with Low Type 2 Inflammation

  • Clairelyne Dupin
  • Sylvain Marchand-Adam
  • Olivier Favelle
  • Romain Costes
  • Philippe Gatault
  • Philippe Diot
  • Leslie Grammatico-Guillon
  • Laurent GuilleminaultEmail author
Original Article

Abstract

Purpose

Little is known about hypogammaglobulinemia (HGG) in asthma patients. No data are available on the characteristics of adult patients with asthma and HGG.

Methods

We conducted a retrospective monocentric study between January 2006 and December 2012. Asthma patients with a serum immunoglobulin (Ig) quantitative analysis were included and classified into two groups depending on their serum IgG concentration: presence or absence of HGG. Clinical, biological, functional, and radiologic characteristics were compared in univariate and multivariate analysis, using a logistic regression model.

Results

In univariate analysis, asthma patients with HGG (n = 25) were older (58 years old ± 18 vs 49 ± 18, p = 0.04) and more frequently active or former smokers as compared to patients with normoglobulinemia (n = 80) (56.0 vs 35.0 %, p = 0.01). Total IgE < 30 kUI/L was more frequently observed in patients with HGG (53.0 vs 18.3 %, p = 0.01). HGG asthma patients had lower fraction of exhaled nitric oxide (p = 0.02), blood eosinophilia (p = 0.0009), and presented with more severe composite score for bronchiectasis (p = 0.01). In multivariate analysis, asthma patients with HGG had increased risk of being smokers [OR = 6.11 (IC 95 % = 1.16–32.04)], having total IgE concentration < 30 kUI/L [OR = 12.87 (IC 95 % = 2.30–72.15)], and a more severe composite score of bronchiectasis [OR = 20.65 (IC 95 % = 2.13–199.74)].

Conclusion

Asthma patients with HGG are older and more often tobacco smoker than asthma patients without HGG. These patients have low type-2 inflammation markers.

Keywords

hypogammaglobulinemia immunoglobulin G asthma inflammation 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare no conflict of interest.

References

  1. 1.
    World Health Organization. Asthma, fact sheet N°307 [Internet]. 2013. Available from: http://www.who.int/mediacentre/factsheets/fs307/en/
  2. 2.
    Borish L, Culp JA. Asthma: a syndrome composed of heterogeneous diseases. Annals Allergy Asthma Immunol. 2008;101:1–9.CrossRefGoogle Scholar
  3. 3.
    Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218–24.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Skloot GS. Asthma phenotypes and endotypes: a personalized approach to treatment. Curr Opin Pulm Med. 2016;22:3–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–73.CrossRefPubMedGoogle Scholar
  6. 6.
    Schatz M, Rosenwasser L. The allergic asthma phenotype. J Allergy Clin Immunol Pract. 2014;2:645–8. quiz 649.CrossRefPubMedGoogle Scholar
  7. 7.
    Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18:716–25.CrossRefPubMedGoogle Scholar
  8. 8.
    Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015;135:299–310. quiz 311.CrossRefPubMedGoogle Scholar
  9. 9.
    Ameratunga R, Brewerton M, Slade C, et al. Comparison of diagnostic criteria for common variable immunodeficiency disorder. Front Immunol. 2014;5:415.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gathmann B, Mahlaoui N, Ceredih, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134:116–26.CrossRefPubMedGoogle Scholar
  11. 11.
    Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92:34–48.CrossRefPubMedGoogle Scholar
  12. 12.
    Agondi RC, Barros MT, Rizzo LV, Kalil J, Giavina-Bianchi P. Allergic asthma in patients with common variable immunodeficiency. Allergy. 2010;65:510–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Thickett KM, Kumararatne DS, Banerjee AK, Dudley R, Stableforth DE. Common variable immune deficiency: respiratory manifestations, pulmonary function and high-resolution CT scan findings. QJM. 2002;95:655–62.CrossRefPubMedGoogle Scholar
  14. 14.
    Urm S-H, Yun HD, Fenta YA, et al. Asthma and risk of selective IgA deficiency or common variable immunodeficiency: a population-based case–control study. Mayo Clin Proc. 2013;88:813–21.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Özcan C, Metin A, Erkoçoğlu M, Kocabas CN. Bronchial hyperreactivity in children with antibody deficiencies. Allergol Immunopathol (Madr). 2015;43:57–61.CrossRefGoogle Scholar
  16. 16.
    Hamilos DL, Young RM, Peter JB, Agopian MS, Iklé DN, Barka N. Hypogammaglobulinemia in asthmatic patients. Ann Allergy. 1992;68:472–81.PubMedGoogle Scholar
  17. 17.
    Baris S, Karakoc-Aydiner E, Ozen A, Ozdemir C, Bahceciler NN, Barlan IB. Serum immunoglobulin levels as a predictive factor for a better outcome of non-atopic childhood asthma. Pediatr Allergy Immunol. 2011;22:298–304.CrossRefPubMedGoogle Scholar
  18. 18.
    Tsai W-J, Lin J-Y, Yang Y-H, Lee J-H, Chiang B-L. Serum immunoglobulin E levels in patients with primary hypogammaglobulinemia - experience from a tertiary hospital in Taiwan. J Microbiol Immunol Infect. 2009;42:271–5.PubMedGoogle Scholar
  19. 19.
    GINA 2015_rev_wms.pdf - GINA_Report_2015_Aug11.pdf, (n.d.) [cited 2016 Aug 3]. http://ginasthma.org/wp-content/uploads/2016/01/GINA_Report_2015_Aug11-1.pdf
  20. 20.
    Agarwal S, Cunningham-Rundles C. Assessment and clinical interpretation of reduced IgG values. Ann Allergy Asthma Immunol. 2007;99:281–3.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Laszlo G. Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force. Thorax. 2006;61:744–6.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5–40.CrossRefPubMedGoogle Scholar
  23. 23.
    Silkoff PE, Erzurum SC, Lundberg JO, et al. ATS workshop proceedings: exhaled nitric oxide and nitric oxide oxidative metabolism in exhaled breath condensate. Proc Am Thorac Soc. 2006;3:131–45.CrossRefPubMedGoogle Scholar
  24. 24.
    McGuinness G, Naidich DP. Bronchiectasis: CT/clinical correlations. Semin Ultrasound CT MR. 1995;16:395–419.CrossRefPubMedGoogle Scholar
  25. 25.
    Judge EP, Dodd JD, Masterson JB, Gallagher CG. Pulmonary abnormalities on high-resolution CT demonstrate more rapid decline than FEV1 in adults with cystic fibrosis. Chest. 2006;130:1424–32.CrossRefPubMedGoogle Scholar
  26. 26.
    Bhalla M, Turcios N, Aponte V, et al. Cystic fibrosis: scoring system with thin-section CT. Radiology. 1991;179:783–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Murray MA, Chotirmall SH. The Impact of Immunosenescence on Pulmonary Disease. Mediators Inflamm. 2015;2015:692546.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Gavazzi G, Krause K-H. Ageing and infection. Lancet Infect Dis. 2002;2:659–66.CrossRefPubMedGoogle Scholar
  29. 29.
    Pawelec G, Akbar A, Beverley P, et al. Immunosenescence and Cytomegalovirus: where do we stand after a decade? Immun Ageing. 2010;7:13.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Holt PG. Immune and inflammatory function in cigarette smokers. Thorax. 1987;42:241–9.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    McMillan SA, Douglas JP, Archbold GP, McCrum EE, Evans AE. Effect of low to moderate levels of smoking and alcohol consumption on serum immunoglobulin concentrations. J Clin Pathol. 1997;50:819–22.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010;34:J258–65.CrossRefPubMedGoogle Scholar
  33. 33.
    Bateman ED, Reddel HK, van Zyl-Smit RN, Agusti A. The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med. 2015;3:719–28.CrossRefPubMedGoogle Scholar
  34. 34.
    Menezes AMB, Montes de Oca M, Pérez-Padilla R, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest. 2014;145:297–304.CrossRefPubMedGoogle Scholar
  35. 35.
    Kauppi P, Kupiainen H, Lindqvist A, et al. Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma. 2011;48:279–85.CrossRefPubMedGoogle Scholar
  36. 36.
    Dati F, Schumann G, Thomas L, et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP Reference Material (CRM 470) Eur J Clin Chem Clin Biochem 1996;34:517–20. International Federation of Clinical Chemistry, Community Bureau of Reference of the Commission of the European Communities, College of American PathologistsGoogle Scholar
  37. 37.
    Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–95.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Hel Z, Huijbregts RPH, Xu J, Nechvatalova J, Vlkova M, Litzman J. Altered serum cytokine signature in common variable immunodeficiency. J Clin Immunol. 2014;34:971–8.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Quinti I, Soresina A, Guerra A, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011;31:315–22.CrossRefPubMedGoogle Scholar
  40. 40.
    Maglione PJ, Overbey JR, Radigan L, Bagiella E, Cunningham-Rundles C. Pulmonary radiologic findings in common variable immunodeficiency: clinical and immunological correlations. Ann Allergy Asthma Immunol. 2014;113:452–9.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Huang YJ, Nariya S, Harris JM, et al. The airway microbiome in patients with severe asthma: associations with disease features and severity. J Allergy Clin Immunol. 2015;136:874–84.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Culić O, Eraković V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol. 2001;429:209–29.CrossRefPubMedGoogle Scholar
  43. 43.
    Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther. 2014;143:225–45.CrossRefPubMedGoogle Scholar
  44. 44.
    Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177:148–55.CrossRefPubMedGoogle Scholar
  45. 45.
    Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68:322–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax. 2004;59:540–1.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660–7.CrossRefPubMedGoogle Scholar
  48. 48.
    Goldacker S, Draeger R, Warnatz K, et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol. 2007;124(3):294–303.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Clairelyne Dupin
    • 1
  • Sylvain Marchand-Adam
    • 1
    • 2
    • 3
  • Olivier Favelle
    • 4
  • Romain Costes
    • 5
  • Philippe Gatault
    • 6
  • Philippe Diot
    • 1
    • 2
    • 3
  • Leslie Grammatico-Guillon
    • 5
    • 7
  • Laurent Guilleminault
    • 1
    • 2
    • 3
    Email author
  1. 1.CHRU Tours, Service de Pneumologie et explorations fonctionnelles respiratoiresHôpital BretonneauTours CedexFrance
  2. 2.Université François RabelaisToursFrance
  3. 3.INSERM, Centre d’Etude des Pathologies RespiratoiresToursFrance
  4. 4.CHRU Tours, Groupement d’imagerie médicaleToursFrance
  5. 5.CHRU Tours, service d’information médicale, d’épidémiologie et d’économie de la santéToursFrance
  6. 6.CHRU Tours, Service de néphrologieToursFrance
  7. 7.Equipe Emergente EE1 Education Ethique SantéUniversité François-RabelaisToursFrance

Personalised recommendations